Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941499 · ClinicalTrials.gov registry record · Phase 1
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT00941499: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00941499 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00941499, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the best combination of oxaliplatin, bevacizumab, 5-fluorouracil, leucovorin, and cetuximab that can be given to patients with advanced cancer that has spread to the liver. Different combinations of these drugs will be used, and the safety of all drug combinations will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Leucovorin
- DRUG Cetuximab
- DRUG 5-FU
- DRUG HAI Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00941499
The ClinicalTrials.gov registry entry for NCT00941499 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00941499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00941499 about?
NCT00941499 is a clinical study titled "Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab". The goal of this clinical research study is to find the best combination of oxaliplatin, bevacizumab, 5-fluorouracil, leucovorin, and cetuximab that can be given to patients with advanced cancer that has spread to the liver. Different combinations of these drugs will be used, and the safety of all d...
What is the current status of trial NCT00941499?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2009-07. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00941499?
The interventions under investigation include: Bevacizumab (DRUG), Leucovorin (DRUG), Cetuximab (DRUG), 5-FU (DRUG), HAI Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00941499?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.